Miraculins Inc. is a Canada-based development stage company focused on in-licensing/acquiring and developing both cancer and non-cancer diagnostic opportunities that have completed early stage research and address unmet clinical needs. The Company’s PreVu Non-Invasive Skin Cholesterol Test (PreVu) test is a non-invasive test which measures cholesterol in the skin tissues to assess risk of coronary artery disease (CAD) or heart disease. The PREVU Skin Cholesterol Test measures skin cholesterol. It also provides collaborators and customers with testing services using its PSP94 RUO kit. The Company has acquired a panel of Preeclampsia biomarkers from Mount Sinai Hospital and partnered the program with Inverness Medical Innovations.